Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling activities underway; First-in-human Phase 1 initiation anticipated by year-end 2025 Strong year-end financial position with cash, cash equivalent and short-term investments of $883.5 million SAN... Read More

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March. Guggenheim SMID Cap Biotech Conference Format: Fireside chat and 1x1 meetings... Read More

Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) --... Read More

SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21,... Read More

First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development... Read More

Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern... Read More

SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced multiple upcoming posters at The Obesity Society's Annual Meeting, ObesityWeek ® , taking place from November 3-6, 2024 in San Antonio, TX. Title: Novel Oral Small Molecule Dual... Read More

SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark... Read More

SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of Shire plc and brings more than 30 years of experience in... Read More

SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc . (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September: Morgan Stanley 22 nd Annual Global Healthcare Conference Fireside chat: Thursday, September 5... Read More

GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter of 2024 Oral small molecule amylin receptor agonist development candidate expected to be selected in the fourth quarter of 2024 Obesity pipeline consists of four oral small molecule programs targeting GLP-1, GIP, amylin and APJ receptors Strong financial position with cash balance of $927.1 million expected to fund projected operations and key... Read More

SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares,... Read More

SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of... Read More

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 8,000,000... Read More

GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the capsule to tablet PK study, in both cases at 12 weeks GSBR-1290 demonstrated generally favorable safety and tolerability results with low AE-related study discontinuations Pharmacokinetic data support dose proportional exposure and... Read More

Topline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Plan to initiate dosing in first-in-human Phase 1 clinical trial of oral small molecule LPA1R Antagonist, LTSE-2578, for idiopathic pulmonary fibrosis in June 2024 SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage... Read More

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on... Read More

Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Year-end cash balance of $467.3 million expected to fund operations and key clinical milestones through 2026 SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) - - Structure... Read More

GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% study discontinuation rate due to adverse events in obesity Topline Phase 2a data from first study in type 2 diabetes mellitus (T2DM) demonstrate significant reductions in hemoglobin A1c (HbA1c) and weight at 12 weeks Interim... Read More

Announced positive results from Phase 1b clinical study of oral GLP-1 receptor agonist, GSBR-1290, demonstrating significant weight loss supporting once-daily dosing and an encouraging safety and tolerability profile Topline data from GSBR-1290 Phase 2a diabetes cohort expected in December 2023; Topline data from Phase 2a obesity cohort expected in first half of 2024 Completed $300 million financing; expected to extend... Read More

GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily dosing Topline data from Phase 2a type 2 diabetes cohort expected in latter half of fourth quarter 2023; topline data from obesity cohort now expected in the first half 2024 Phase 2b studies in type 2 diabetes and obesity planned for... Read More

$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents and short-term investments, are expected to extend cash runway through the end of 2026 SAN FRANCISCO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical... Read More

Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic... Read More

SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that it has appointed Ted W. Love, M.D., to its Board of Directors. Dr. Love brings more than 30 years of experience in the biopharmaceuticals industry, and currently chairs the... Read More

SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc . (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that clinical and preclinical data from its oral GLP-1 receptor agonist GSBR-1290 program will be presented at the upcoming American Diabetes Association (ADA)... Read More

SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 9:30 AM... Read More

12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and formulation bridging study planned to evaluate tablet formulation in preparation for global Phase 2b study of GSBR-1290 in 2024 SAN FRANCISCO and SHANGHAI, China, May 25, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc.... Read More

SAN FRANCISCO and SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that the Company will present three scientific posters at the upcoming 2023 American Thoracic Society (ATS) International Conference taking place May 19-24, 2023,... Read More

Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half 2023 SAN FRANCISCO and SHANGHAI, May 11, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and... Read More

Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290 Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023 Completed $185.3 million upsized initial public offering SAN FRANCISCO and SHANGHAI, March 30, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic... Read More

SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the closing of its previously announced upsized initial public offering of 12,351,000 American depositary shares (ADSs), each representing three ordinary shares,... Read More